# Image Eval Diagnostics: iter2_infer_variables_sonnet46_retry1

## Bucket Counts

- missed node: 9
- extra hallucinated node: 9
- wrong branch direction/label: 9
- variable extraction miss: 9
- ambiguity unresolved: 9

## Per-Case Bucket Distribution

### diabetes_treatment
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

### liver_pathology
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

### workflow_test
- missed node: 3
- extra hallucinated node: 3
- wrong branch direction/label: 3
- variable extraction miss: 3
- ambiguity unresolved: 3

## Trial Notes

### workflow_test trial 1 - composite 47.24
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The 'Consider Lipid Clinic Referral' and 'Refer to specilaist' outputs appear side-by-side after 'Are They Optimised on treatment? - Yes' in the upper branch; it is unclear if both are always shown or if there is a further decision between them.; The 'not coded, assume no' yellow note implies a default value for Under Specialist Clinic; it is unclear if this is a user input or a system default.; The LDL branch from 'Assess LDL' has three paths: LDL ≤2, LDL 2-2.5, and LDL ≥2.6. The diagram is not fully clear on whether LDL 2-2.5 leads directly to the Inclisiran/Ezetimibe sub-branch or if there is an intermediate step.; The 'Consultation' label near 'Send Lipid Lowering Therapy AccuRx' (upper branch, optimised - No) is ambiguous - it is unclear if it is a separate output or just a label.; The flow from the upper 'Primary/Secondary Treatment' node back to the main raised cholesterol path is ambiguous - it is unclear if this is a loop or a separate entry point.

### workflow_test trial 2 - composite 43.76
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has a note 'not coded, assume no' next to the Under Specialist Clinic? decision - it is unclear if this means the default is always 'No' or if it's a data quality note.; The 'Total Cholesterol Result' thresholds (≤7.5 and >7.5) are shown on the diagram, but the 'Normal or Raised?' branch seems to use a separate concept of normal vs raised. It's unclear if these map to the same input or separate inputs.; The 'Assess LDL' node branches into LDL ≥2.6, LDL 2-2.5, and LDL ≤2 - three branches from what appears to be one decision node. This has been modeled as nested decisions but the exact diagram structure is ambiguous.; The Inclisiran pathway (Has had 6 months / Hasn't had 6 months -> Repeat Lipids at 3 months -> LDL >2.0 -> Add in Ezetimibe) appears to branch off the Initiate Inclisiran output node, but outputs should have no children per the rules - this secondary pathway after Inclisiran initiation has been omitted.; The 'Are They Optimised on treatment?' node near the top (for primary/secondary treatment path) and the one lower for patients taking lipid lowering therapy appear to be two separate decision nodes with the same label but different contexts.

### workflow_test trial 3 - composite 42.35
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has a separate upper path for patients already on Primary/Secondary Treatment who are asked 'Are They Optimised on treatment?' (top area) with branches to 'Consider Lipid Clinic Referral', 'Refer to specialist', and 'Send Lipid Lowering Therapy AccuRx'. It is unclear how this path connects to the main flow starting from 'Assess Total Cholesterol Result'.; The 'Assess LDL' node in the secondary prevention path branches into LDL 2-2.5, LDL ≥ 2.6, and LDL ≤ 2. The connection between the secondary maximally-tolerated-statin path and the 'Assess LDL' node is complex and it is ambiguous whether the QRISK2/3 calculation is also used in secondary prevention.; The 'Repeat Lipids at 3 months' output connects back upstream in the diagram (to 'Assess LDL' via 'LDL >2.0' decision after Inclisiran path), creating a cycle which cannot be represented in a strict tree structure.; The 'not coded, assume no' annotation near 'Under Specialist Clinic?' suggests a default value assumption; it is unclear if this should be an explicit input default.; The top path 'Are They Optimised on treatment?' (green box) appears to be a separate entry point for patients already on Primary/Secondary Treatment, making the overall workflow potentially multi-rooted.

### diabetes_treatment trial 1 - composite 28.57
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows two separate Metformin starting points (CVD/risk path and non-CVD path) both leading to escalation; the tree merges these into separate branches but the diagram's layout makes it ambiguous whether they truly diverge from a single CVD decision or are independent entry points.; For the CVD pathway, when SGLT2i is tolerated, it is unclear whether 'A1c not controlled' leads directly to Ozempic or if there is an intermediate dual/triple therapy step before Ozempic.; The 'Not tolerated** switch to' label in the diagram points from the SGLT2i box back toward Ozempic, but it is ambiguous whether this means switching from Metformin entirely or just the SGLT2i add-on.; The Minimum BMI for GLP Initiation is 23 box appears in the CVD pathway near the SGLT2i/Ozempic transition, but it is unclear if it applies to all GLP initiations or only in the CVD pathway.; The 'Despite Optimisation and maximally tolerated dose A1C >58' node and 'Refer to Insulin Initiator' appear to apply to both the CVD Ozempic pathway and the non-CVD triple therapy Ozempic pathway; the diagram's exact routing is ambiguous.

### diabetes_treatment trial 2 - composite 23.85
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has multiple overlapping pathways (CVD/Risk pathway and non-CVD pathway) that are difficult to represent as a single strict tree without duplication. Some nodes appear to be shared endpoints.; The 'Not tolerated** switch to' branch on the CVD pathway is ambiguous - it's unclear what medication replaces Metformin before SGLT2i.; The relationship between the triple therapy pathway and the CVD/Risk pathway's Ozempic/Refer to Insulin Initiator nodes is unclear - they may be shared or separate.; The Symptoms & New A1c >58 branch appears to feed into the Admission required? decision, but also the non-symptomatic path starts directly with Metformin - the exact branching logic from Treatment Algorithm is ambiguous.; The 'A1c not controlled' decision after SGLT2i in CVD pathway flows to Minimum BMI check then Ozempic, but the diagram also shows a separate 'Refer to Insulin Initiator' if Ozempic fails - the exact sequence is not fully clear.

### diabetes_treatment trial 3 - composite 30.13
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram shows 'Symptoms & New A1c >58' feeding into 'Admission required?' on the non-CVD pathway, but it's unclear whether the Metformin branch (non-CVD, no symptoms) also passes through the symptoms check or starts directly at Metformin.; The 'Not tolerated** switch to' path in the CVD branch is ambiguous - it is unclear if it goes directly to Ozempic or through a BMI check at 23; the diagram shows 'Minimum BMI for GLP Initiation is 23' as an informational box, not clearly a decision node.; The 'High prognostic value' / 'Low prognostic value' split after 'Add GLP' in the triple therapy section is ambiguous - it's unclear if Ozempic and Mounjaro are alternatives or sequential, and whether the 'Despite Optimisation A1C >58' box applies only to the Ozempic branch.; It is unclear whether the CVD pathway and non-CVD pathway both start from the Treatment Algorithm node or if CVD Known or Risk is checked before symptoms.; The diagram shows Gliclazide as an option in both dual therapy and as a standalone treatment for symptoms+A1c>58 without admission; the relationship between these is ambiguous.

### liver_pathology trial 1 - composite 17.32
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has many parallel/concurrent branches (mandatory testing, conditional testing, NAFLD score, FIB4 categories) emanating from 'Phase 4 Bloods', but the tree model only allows a single child per action node. These have been linearized which may not fully represent the parallel nature.; The 'Review Result' node receives inputs from multiple conditional testing branches (Haemochromatosis Gene Test, Primary Biliary Cirrhosis Screen, MRCP, Autoimmune Hepatitis screens) but a tree structure cannot represent multiple parents feeding into a single node.; The NAFLD Fibrosis Score thresholds differ by age (<65: -1.455/0.675, ≥65: -2.0/0.675) — the exact age cutoff logic is complex and partially illegible in the diagram.; The FIB-4 thresholds also differ by age (<65: 1.3/2.67, ≥65: 2.0/2.67) — partially illegible.; The 'Code as normal USS and file' branch from 'Recheck Baseline Liver Profile' — it is unclear if this applies when abnormalities are not sustained or when a different condition is met.

### liver_pathology trial 2 - composite 13.67
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has several feedback loops (e.g., Telephone Consultation feeding back into Phase 4 Bloods, and Recheck looping back to Phase 3). These cycles cannot be represented in a strict tree; they have been approximated with terminal action nodes.; The 'Review Result' node appears to be shared by multiple branches (after Haemochromatosis, PBC Screen, Autoimmune Screen). In the tree, it is placed after PBC Screen only; other branches terminate without it.; FIB-4 age-adjusted thresholds (<2.0 if age >=65 instead of <1.3) and (>=2.0 if age >=65 for intermediate) are noted in the diagram but complex age-conditional logic is only partially captured in conditions.; The 'Fibrous Scan if available' node appears twice in different branches (Indeterminate NAFLD and Intermediate/High FIB-4). These are represented as separate nodes.; The exact flow between Conditional Testing sub-branches (NAFLD Score vs FIB-4 vs UC/PANCA vs IgG) is not fully clear from the diagram—they may be parallel rather than sequential.

### liver_pathology trial 3 - composite 12.71
- Buckets: missed node, extra hallucinated node, wrong branch direction/label, variable extraction miss, ambiguity unresolved
- Doubts: The diagram has many converging arrows and feedback loops (e.g., Review Result feeds back into Telephone Consultation and then No Concern or referral) which are difficult to represent as a strict tree without duplicating nodes.; The 'Phase 4 Bloods' node appears multiple times in the diagram with arrows converging from different branches (NAFLD score, FIB-4 score, rare conditions); it is unclear if this is a single shared node or separate instances.; The 'Telephone Consultation' node appears to receive inputs from multiple branches (Review Result abnormal, and directly from the rare conditions branch); exact branching logic is ambiguous.; The 'Need to rationalise which Additional tests should be done for rare conditions' branch and its relationship to Mandatory Testing vs Conditional Testing is not fully clear from the diagram resolution.; FIB-4 thresholds differ by age (1.3 general, 2.0 for age 65+, 2.67 high risk); age input is not explicitly shown as a separate input node in the diagram.
